National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States
Open Access
- 28 August 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (11) , 2010-2019
Abstract
Organ transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV (HIV D+/R+) presents risks of donor-derived infections. Understanding clinical, immunologic, and virologic characteristics of HIV-positive donors is critical for safety. We performed a prospective study of donors with HIV-positive and HIV false-positive (FP) test results within the HIV Organ Policy Equity (HOPE) Act in Action studies of HIV D+/R+ transplantation (ClinicalTrials.gov NCT02602262, NCT03500315, and NCT03734393). We compared clinical characteristics in HIV-positive versus FP donors. We measured CD4 T cells, HIV viral load (VL), drug resistance mutations (DRMs), coreceptor tropism, and serum antiretroviral therapy (ART) detection, using mass spectrometry in HIV-positive donors. Between March 2016 and March 2020, 92 donors (58 HIV positive, 34 FP), representing 98.9% of all US HOPE donors during this period, donated 177 organs (131 kidneys and 46 livers). Each year the number of donors increased. The prevalence of hepatitis B (16% vs 0%), syphilis (16% vs 0%), and cytomegalovirus (CMV; 91% vs 58%) was higher in HIV-positive versus FP donors; the prevalences of hepatitis C viremia were similar (2% vs 6%). Most HIV-positive donors (71%) had a known HIV diagnosis, of whom 90% were prescribed ART and 68% had a VL <400 copies/mL. The median CD4 T-cell count (interquartile range) was 194/µL (77–331/µL), and the median CD4 T-cell percentage was 27.0% (16.8%–36.1%). Major HIV DRMs were detected in 42%, including nonnucleoside reverse-transcriptase inhibitors (33%), integrase strand transfer inhibitors (4%), and multiclass (13%). Serum ART was detected in 46% and matched ART by history. The use of HIV-positive donor organs is increasing. HIV DRMs are common, yet resistance that would compromise integrase strand transfer inhibitor–based regimens is rare, which is reassuring regarding safety.Keywords
Funding Information
- National Institutes of Health (R01 AI20938, U01 AI138897, U01 AI134591)
- Division of Intramural Research
- National Institute of Diabetes and Digestive and Kidney Diseases (K24 AI144952)
- American Society of Transplantation (gSAN-201C0WW)
- Johns Hopkins School of Medicine
- Johns Hopkins University Center for AIDS Research (P30 AI094189)
- The Living Legacy Foundation
This publication has 34 references indexed in Scilit:
- Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive DonorsAnnals of Internal Medicine, 2016
- Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysisThe Lancet Infectious Diseases, 2016
- From Bench to BillAnnals of Surgery, 2016
- Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
- Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2015
- Characteristics and genotype profiles of antiretroviral-naïve patients entering a Southern US HIV outpatient clinic 2009–2012International Journal of STD & AIDS, 2015
- An Assessment of HIV-Infected Patients Dying in Care for Deceased Organ Donation in a United States Urban CenterAmerican Journal of Transplantation, 2015
- Estimating the Potential Pool of HIV-Infected Deceased Organ Donors in the United StatesAmerican Journal of Transplantation, 2011
- Renal Transplantation between HIV-Positive Donors and RecipientsNew England Journal of Medicine, 2010
- Epidemiology of Hepatitis B Virus Infection in a US Cohort of HIV‐Infected Individuals during the Past 20 YearsClinical Infectious Diseases, 2010